Emerging treatments

Inhibition strategies

Efficacy of the mammalian target of rapamycin (mTOR) inhibitor everolimus, and the anti-angiogenesis agent axitinib, in preventing the formation and progression of spinal melanoma metastases has been demonstrated in an animal model, although the therapeutic effect was mild.[90] Other emerging systemic therapies aimed at preventing bone metastases include chemotherapy and other antiresorptive molecules, such as inhibitors of RANK/RANKL (receptor activator of nuclear factor-kappa-B ligand).[91]

Other drug treatments

Several drugs have emerged as potentially part of therapy for bone metastases and MSCC. These include denosumab and the bisphosphonate zoledronic acid.[92]

Use of this content is subject to our disclaimer